{"id":24699,"date":"2024-02-08T14:17:58","date_gmt":"2024-02-08T14:17:58","guid":{"rendered":"https:\/\/faceinews.com\/?p=24699"},"modified":"2024-02-08T14:17:58","modified_gmt":"2024-02-08T14:17:58","slug":"first-private-hospital-in-india-to-successfully-complete-car-t-cell-therapy-now-introduces-made-in-india-car-t-cell-program","status":"publish","type":"post","link":"https:\/\/www.faceinews.com\/?p=24699","title":{"rendered":"First Private Hospital in India to Successfully Complete CAR T Cell Therapy. Now introduces Made in India, CAR T Cell Program"},"content":{"rendered":"<p><a href=\"https:\/\/faceinews.com\/wp-content\/uploads\/2024\/02\/Photo1_copy_668x443.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-medium wp-image-24700\" src=\"https:\/\/faceinews.com\/wp-content\/uploads\/2024\/02\/Photo1_copy_668x443-300x199.jpg\" alt=\"\" width=\"300\" height=\"199\" srcset=\"https:\/\/www.faceinews.com\/wp-content\/uploads\/2024\/02\/Photo1_copy_668x443-300x199.jpg 300w, https:\/\/www.faceinews.com\/wp-content\/uploads\/2024\/02\/Photo1_copy_668x443.jpg 668w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>from Left to Right &#8211;<\/p>\n<p>Ms. Sheelaketan, Chief Executive Officer, Apollo Cancer Centre, Chennai<\/p>\n<p>Mr Harshad Reddy, Director &#8211; Group Oncology &amp; International, Apollo Hospitals Enterprise Ltd<\/p>\n<p>Dr. T Raja, Director of Medical Oncology at Apollo Cancer Centre, Chennai<\/p>\n<p>Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd<\/p>\n<p>Dr Revathi Raj, Senior Consultant &#8211; Paediatric Haematology Oncology, Apollo Cancer Centre, Chennai<\/p>\n<p><a href=\"https:\/\/faceinews.com\/wp-content\/uploads\/2017\/11\/Faceinews-Logo-Copy.png\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-7654 alignnone\" src=\"https:\/\/faceinews.com\/wp-content\/uploads\/2017\/11\/Faceinews-Logo-Copy.png\" alt=\"\" width=\"173\" height=\"43\" \/><\/a><\/p>\n<p>First Private Hospital in India to Successfully Complete CAR T Cell Therapy. Now introduces Made in India, CAR T Cell Program<\/p>\n<p><iframe loading=\"lazy\" title=\"CAR T Cell Program 1st Pvt Hospital in India to Complete CAR T Cell Therapy.introduces Made in India\" width=\"598\" height=\"336\" src=\"https:\/\/www.youtube.com\/embed\/TWoxIyAdOkQ?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n<p>&nbsp;<\/p>\n<p>Chennai, \u2013 February 8th, 2024 \u2013 In a ground-breaking development, Apollo Cancer Centres (ACCs) has emerged as the first private hospital group in India to have a successfully complete CAR-T cell program and to further augment it, the group will now provide access to \u2018Made in India\u2019 CAR-T cell therapy, beginning with NexCAR19\u2122 (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 years and above.<\/p>\n<p><a href=\"https:\/\/faceinews.com\/wp-content\/uploads\/2024\/02\/Photo-2_copy_800x533.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-medium wp-image-24701\" src=\"https:\/\/faceinews.com\/wp-content\/uploads\/2024\/02\/Photo-2_copy_800x533-300x200.jpg\" alt=\"\" width=\"300\" height=\"200\" srcset=\"https:\/\/www.faceinews.com\/wp-content\/uploads\/2024\/02\/Photo-2_copy_800x533-300x200.jpg 300w, https:\/\/www.faceinews.com\/wp-content\/uploads\/2024\/02\/Photo-2_copy_800x533-768x512.jpg 768w, https:\/\/www.faceinews.com\/wp-content\/uploads\/2024\/02\/Photo-2_copy_800x533.jpg 800w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>Marking a historic moment in the country&#8217;s medical landscape, Dr. T Raja, Director of Medical Oncology at ACC, Chennai, spearheaded the development of this revolutionary clinical program, and has successfully treated six patients till date.<\/p>\n<p>CAR-T cell therapies, often known as \u2018living drugs\u2019 involve the extraction of a patient\u2019s T-cells (a type of white blood cells whose function is to fight cancer cells) through a process known as Apheresis. These T-cells are then genetically modified by a safe vehicle (viral vector) in a controlled laboratory setting, so that they express modified connectors on their surface called Chimeric Antigen Receptors (CARs). These CARs are specifically designed to recognize a protein which is abnormally expressed on certain cancer cells. They are then multiplied to a desired dose and infused directly into the patient.<\/p>\n<p>More than 25,000 patients have received this treatment modality. It is currently primarily indicated for patients with aggressive B cell Lymphomas, B cell Acute Lymphoblastic Leukemia(B-ALL) and Multiple Myeloma.<\/p>\n<p>Dr. Raja, said, &#8220;The successful treatment of six patients using CAR-T Cell therapy, using both clinical trial option and with commercial option, represents a significant leap forward in our fight against B-cell lymphomas and acute lymphoblastic leukaemia. These cases highlight the efficacy and potential of this transformative therapy in providing new hope for patients facing these challenging conditions.&#8221;<\/p>\n<p>Sharing insights into the success of the program, he further added, &#8220;Having successfully treated patients with imported drugs, we are now poised to treat them with the indigenously built therapy.\u201d<\/p>\n<p>On the occasion, Ms Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd, said &#8220;Our successful clinical CAR-T cell program at Apollo Cancer Centres stands as a testament to our commitment to advancing precision oncology. Under the visionary leadership of Dr. T Raja, Director of Medical Oncology, our journey into gene-modified cell therapy signifies a new era in innovative cancer treatments, ensuring cutting-edge solutions for those facing B-cell lymphomas and B-acute lymphoblastic leukaemia. This further solidifies Apollo&#8217;s dedication to delivering state-of-the-art clinical interventions, shaping the future of cancer care in India.&#8221;<\/p>\n<p>Dr Revathi Raj, Senior Consultant &#8211; Paediatric Haematology Oncology, Apollo Cancer Centres, said, &#8220;I am thrilled to witness the groundbreaking success of Apollo Cancer Centres&#8217; CAR-T Cell Therapy program, particularly the introduction of NexCAR19\u2122, as it offers new hope for cancer patients fighting B-cell lymphomas and acute lymphoblastic leukemia. The achievement of successful clinical trials and commercial treatments at Apollo Cancer Centres represents a significant milestone in advancing cancer care, making it a historic moment in the country&#8217;s medical landscape. This transformative and accessible treatment will undoubtedly have a profound impact on cancer patients, reaffirming our dedication to pushing healthcare boundaries and delivering cutting-edge solutions to the community.&#8221;<\/p>\n<p>Apollo Cancer Centres has been a trailblazer in the Indian medical community, consistently introducing pioneering medical infrastructure and achieving numerous milestones. The introduction of CAR-T Cell therapy represents a new era for cancer treatment in the country.<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n<p>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>from Left to Right &#8211; Ms. Sheelaketan, Chief Executive Officer, Apollo Cancer Centre, Chennai Mr Harshad Reddy, Director &#8211; Group Oncology &amp; International, Apollo Hospitals Enterprise Ltd Dr. T Raja, Director of Medical Oncology at Apollo Cancer Centre, Chennai Dr Preetha Reddy, Executive Vice Chairperson, Apollo Hospitals Enterprise Ltd Dr Revathi Raj, Senior Consultant &#8211; [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":24700,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[10,31,11,27,34,28],"tags":[],"class_list":["post-24699","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-corporate","category-health","category-new-hopes","category-news","category-technology","category-value-added-services"],"_links":{"self":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts\/24699","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=24699"}],"version-history":[{"count":2,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts\/24699\/revisions"}],"predecessor-version":[{"id":24703,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/posts\/24699\/revisions\/24703"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=\/wp\/v2\/media\/24700"}],"wp:attachment":[{"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=24699"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=24699"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.faceinews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=24699"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}